Author: admin

United States ISM Manufacturing PMI below forecasts (48.6) in November: Actual (48.2)

• Prior month 48.7
• ISM Manufacturing PMI index xx.x vs. 49.0 expected
• Prices Paid xx.x vs 57.0 estimate. Prior month 58.0
• Employment index xx.x vs 46.0 last month.
• New orders xx.x vs 49.4 last month
• Production xx.x vs 48.2 last month
• Supplier deliveries xx.x vs 54.2 last month.
• Inventories xx.x vs 45.8 last month.
• Customer inventories xx.x vs 43.9 last month.
• Backlog of orders xx.x vs 47.9 last month
• New Export orders xx.x vs 44.5 last month
• Imports xx.x vs 45.4 last month

This article was written by Greg Michalowski at investinglive.com.

United States ISM Manufacturing Employment Index declined to 44 in November from previous 46

United States ISM Manufacturing New Orders Index dipped from previous 49.4 to 47.4 in November

Copper and PGMs stand out as traders aggressively stockpile metals, straining already thin global inventories.

Sector Overview

Today’s US stock market heatmap reveals significant sector disparities, with the Technology sector seeing substantial weaknesses, while Healthcare demonstrates resilience. Key tech players like Microsoft (MSFT) and Palantir (PLTR) are down by 1.03% and 2.53% respectively, indicating bearish sentiment within software infrastructure.

📉 Technology Sector Declines

• Microsoft (MSFT) has faced a decline of 1.03%, highlighting challenges within software infrastructure.
• Nvidia (NVDA) and Advanced Micro Devices (AMD) are also down by 1.30% and 1.43%, contributing to a negative semiconductor outlook.
• Palantir (PLTR) stands out with a significant drop of 2.53%, hinting at specific concerns or broader sector challenges.

🔬 Healthcare Resilience

• Eli Lilly (LLY) edges up by 0.06%, reinforcing stability and positive sentiment within the healthcare sector.
• Merck & Co (MRK) remains steady with a minor uptick of 0.29%, supporting the consistent performance in pharmaceuticals.

Market Mood and Trends

Overall market sentiment leans towards caution, with technology stocks generally underperforming due to potential industry-specific concerns and investor hesitancy. However, healthcare’s steadiness provides a counterbalance to today’s market dynamics. Investors seem wary of making aggressive moves amidst technology-driven volatility.

Strategic Recommendations

Investors should consider shifting focus towards the healthcare sector to capitalize on its steady performance amidst today’s tech sell-off. Keeping a close watch on the semiconductor space is advisable, especially given the declines in key players like NVDA and AMD.

For those considering diversification strategies, balancing tech exposure with healthcare might prove beneficial. It’s vital to remain vigilant against ongoing shifts in investor sentiment, with an eye on emerging opportunities in non-tech sectors.

Stay updated with real-time data and market analyses at InvestingLive.com for comprehensive insights and strategic portfolio adjustments.

This article was written by Itai Levitan at investinglive.com.

• Prior month 51.9

Details from S&P Global:

• Operating conditions improved for the fourth straight month in November, supported by a solid rise in production and further job gains.

• Overall performance was held back by a sharp slowdown in demand growth, driven by weaker sales.

• Weak demand caused an unprecedented second straight monthly surge in finished-goods inventories, the largest rise in the survey’s 18-year history.

• Inflation pressures remained historically elevated, with tariffs frequently cited for pushing input costs higher.

• Manufacturers passed along less of the cost increase, resulting in one of the lowest selling-price inflation readings of the year amid intense competition and soft demand.

• The headline S&P Global US Manufacturing PMI registered 52.2, down from 52.5, signaling continued—but slower—expansion.

• Output rose at the fastest pace since August, supported by gains in both new and existing client orders.

• Despite the uptick in orders, overall demand was only modest and slower than October due to ongoing uncertainty.

• Export demand remained a drag, with new export orders falling for the fifth consecutive month—the steepest drop since July—linked to tariffs and weaker demand from neighboring and Asian markets.

• Sales fell short of expectations for some firms, leading to unintended stockpiling as production outpaced orders.

• Business confidence jumped to its highest level since June, driven by plans for new products, higher investment, and expectations of stronger government spending after the federal shutdown ended.

• Firms added staff to fill vacancies and in anticipation of rising production and sales; employment growth was the strongest in three months.

• Backlogs of work fell modestly for the third month in a row, indicating firms kept ahead of workloads.

• After stockpiling earlier in the year, firms were cautious with purchasing; input buying rose only marginally.

• Supplier delivery times worsened for a third consecutive month, with logistical delays at tariff-affected borders cited.

• Tariffs continued to fuel elevated input-price inflation, especially in metals, while selling-price inflation—though still marked—eased to one of its lowest levels this year.

The more important ISM Manufacturing PMI for November will be released at the top of the hour with expectations of 49.0 versus 48.7 last month. The price is paid index is expected at 57.0 versus 58.0. The employment index came in at 46.0 last month while the new orders were at 49.4 last month

This article was written by Greg Michalowski at investinglive.com.

United States S&P Global Manufacturing PMI above forecasts (51.9) in November: Actual (52.2)

The British Pound (GBP) softens against the Japanese Yen (JPY) at the start of the week as hawkish comments from the Bank of Japan (BoJ) Governor Kazuo Ueda lift the Yen across the board. GBP/JPY trades near 205.25 at the time of writing, marking its lowest level in five days.

USTR is confirming earlier reports that there is an agreement in principle on pharmaceutical pricing between the US and UK.

• The deal secured continued UK invested by UK pharmaceutical companies in the US
• Deal will strengthen supply chains a great job in the US.
• Administration is reviewing drug pricing practices of many other US trade partners.
• Deal calls for UK NHS to increase that price it pays for new medicines by 25%.
• US will refrain targeting UK pharmaceutical pricing practices and any future section 301 investigation

This article was written by Greg Michalowski at investinglive.com.